Krebs Biochemicals & Industries Limited is an Indian pharmaceutical manufacturer specializing in **Active Pharmaceutical Ingredients (APIs)** and **Key Starting Materials (KSMs)**. The company integrates core competencies in **fermentation**, **biocatalysis**, and **complex chemistry** to serve niche global and domestic markets. Currently, the company is undergoing a strategic turnaround focused on transitioning from traditional product sales to a high-utilization **contract manufacturing** and **job work** model. --- ### **Strategic Partnership & Promoter Ecosystem** The company’s operational viability is deeply integrated with its promoter, **Ipca Laboratories Limited**. This relationship provides a critical framework for financial stability and market access. * **Operational Integration:** The partnership includes **contract manufacturing**, **loan license** arrangements, and the conversion of materials on a **job work basis**. * **Forward Integration:** Krebs leverages Ipca’s extensive marketing reach and forward integration into finished dosage forms. * **Financial Framework:** A high-value transaction framework is in place with Ipca, approved for up to **₹120 Crore** for FY 2025-26 and 2026-27 (following a **₹150 Crore** limit in FY 2024-25). * **Asset Leasing:** Ipca provides an **Interest-Free Refundable Lease Deposit** of **₹45 Crore** for the lease-cum-manufacturing agreements of both primary units. --- ### **Manufacturing Infrastructure & Technical Capabilities** The company operates two multipurpose facilities in **Andhra Pradesh**, each with a distinct strategic focus and regulatory profile. | Facility | Location | Focus & Status | Key Metrics / Accreditations | | :--- | :--- | :--- | :--- | | **Unit I** | **Nellore** | High-volume APIs & Import Substitutes | Commercial production of new processes began **May 2023**; currently recovering costs. | | **Unit II** | **Anakapalli (Vizag)** | Intermediates & Job Work | **EDQM, Europe** certified; utilizes non-fermentation processes to reduce energy costs. | **Technical Standards:** * Adherence to **cGMP practices** and **ALCOA principles** (Attributable, Legible, Contemporaneous, Original, and Accurate). * **Unit II** is accredited for global regulatory standards, while **Unit I** serves as a qualified vendor for international clientele. --- ### **Product Portfolio & R&D Pipeline** Krebs is shifting toward higher capacity utilization by introducing new products and optimizing chemical processes to reduce **Raw Material (RM)** costs. * **Key Intermediates:** * **3 APC:** Capacity of **20 TPM** (Produced **64 T** in FY22-23). * **DBA:** Capacity of **15 TPM** (Produced **56 T** in FY22-23). * **Pipeline & Validation:** * **Simvastatin:** New technology received from in-house R&D; currently in the **validation and commercialization** phase. * **3 HAP:** Process validation completed at the Nellore plant. * **R&D Strategy:** While recent fiscal periods showed **Zero R&D expenditure** to focus on absorbing existing technologies, the long-term focus remains on developing **new APIs** to utilize **idle equipment** and validating **import substitutes** to de-risk the supply chain. --- ### **Financial Performance & Capital Structure** The company has faced significant financial headwinds, characterized by persistent net losses and the erosion of reserves. **Three-Year Financial Summary:** | Particulars (₹ in Lakhs) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Turnover** | **4,331.19** | **5,042.15** | **5,213.44** | | **Net Loss** | **(2,693.93)** | **(1,972.84)** | **(2,469.19)** | | **Reserves & Surplus** | **(16,780.00)** | **(14,078.00)** | **(12,102.00)** | **Capital & Debt Profile:** * **Authorized Share Capital:** **₹153 Crore** (**₹23 Cr** Equity; **₹130 Cr** Preference). * **Paid-up Capital:** **₹151.56 Crore**, including **1,30,00,000 9% Non-convertible, Redeemable, Non-cumulative preference shares** issued to Ipca Laboratories. * **Debt Classification:** Under **Ind AS 32**, the **₹130 Crore** in Preference Shares are classified as **Debt under Term Loans**. * **Liquidity Management:** Maintains a **₹10 Crore** Overdraft against Fixed Deposit (**ODFD**) with **RBL Bank** at **8.20% p.a.** to manage cash flow mismatches. --- ### **Leadership Transition & Strategic Recovery Plan** To address material uncertainties, the company has restructured its leadership to focus on technical and financial stabilization. * **New Leadership:** **Mr. Manish Kumar Jain** was appointed as **MD and CEO** for a **5-year term** (August 2025 – August 2030), succeeding **Mr. Jitendra Shah**. * **Remuneration:** Set at **Rs. 2,50,000 per month**, guaranteed even in the event of loss or inadequate profits. * **Recovery Pillars:** 1. **Cost Optimization:** Rationalizing operations to improve margins. 2. **Volume Expansion:** Increasing sales from both existing and new third-party customers. 3. **Financial Backing:** Secured a **confirmation of financial support** from the Holding Company to mitigate liquidity risks. --- ### **Risk Factors & Mitigation** #### **Operational & Regulatory Risks** * **Facility Closure:** The **Vizag unit** remains closed as of **February 2026** following a "stop production" order from the **Andhra Pradesh Pollution Control Board (APPCB)** issued in early 2025. * **Compliance Lapses:** The company has faced challenges regarding **Board Composition** (Independent Director vacancy in early 2025) and **Statutory Auditor** tenure requirements. * **Input Costs:** Margins are sensitive to volatile **coal, energy, and solvent prices**, as well as rising **effluent treatment** expenses. #### **Financial & Legal Risks** * **Going Concern Uncertainty:** Total liabilities exceed total assets by **₹146.24 Crore** (as of FY 2024-25). * **Contingent Liabilities:** * **Income Tax:** **₹10.59 Crore** under appeal. * **Customs/EPCG:** **₹1.49 Crore** for non-compliance. * **Labor/PF/ESI:** Combined claims of approximately **₹1.52 Crore** in damages and interest. #### **Mitigation Strategy** The company is mitigating these risks by aligning wage structures with new **Labour Codes** (effective **Nov 21, 2025**) to limit gratuity liabilities, pursuing **fermentation-based tie-ups** to diversify revenue, and relying on the **arm’s length** financial support of **Ipca Laboratories** to maintain operational continuity.